Mage Biologics makes its debut



A new special purpose biotech company, Mage Biologics Inc, has been launched in the US to advance development of a monoclonal antibody treatment for ulcerative colitis, a chronic, inflammatory bowel disease. The candidate product is being designed for oral administration, using sustained release technology designed by one of its founders.